Sugi Predict

Sugi Predict / Compounds / SCHEMBL3064713

SCHEMBL3064713

SCHEMBL3064713

O=C1CNC(=O)N1C1CCNCC1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ OPRM1 P35372 1/20 0.35
▸ OPRD1 P41143 1/20 0.35
▸ OPRK1 P41145 1/20 0.35
▸ OGFRL1 Q5TC84 1/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ PKM P14618 1/20 0.34
▸ ALOX15 P16050 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ SLC6A2 P23975 2/20 0.33
▸ SLC6A4 P31645 2/20 0.33
▸ SLC6A3 Q01959 2/20 0.33
▸ TSHR P16473 1/20 0.31
▸ PLAT P00750 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17961771 0.88 HTR3E (0.34) OPRM1OPRD1OPRK1OGFRL1SLC6A2
SCHEMBL17961770 0.88 HTR3E (0.34) OPRM1OPRD1OPRK1OGFRL1SLC6A2
SCHEMBL11410317 0.87 OPRM1 (0.38) OPRM1OPRD1OPRK1OGFRL1ALDH1A1
Trifluoroacetic Acid SCHEMBL3816989 0.85 TSHR (0.33) PKMTSHRPLAT
SCHEMBL6230172 0.81 OPRM1 (0.49) OPRM1OPRD1OPRK1OGFRL1ALDH1A1
SCHEMBL791794 0.78 OPRM1 (0.34) OPRM1OPRD1OPRK1OGFRL1MEN1
SCHEMBL3071129 0.76 TP53 (0.34) OPRM1OPRK1MEN1ALDH1A1MAPT
Hydrochloric Acid SCHEMBL11250722 0.74 TP53 (0.33) OPRM1OPRK1MEN1ALDH1A1MAPT
SCHEMBL1970539 0.73 MEN1 (0.50) OPRM1OPRD1OPRK1OGFRL1MEN1
SCHEMBL1970541 0.73 MEN1 (0.50) OPRM1OPRD1OPRK1OGFRL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3914600-B1 THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2024-08-07 — — EP claimed
US-20240279338-A1 Combination Treatment of Cancer ARES TRADING SA (CH) 2024-08-22 — — US disclosed
EP-3468953-B1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 GLAXOSMITHKLINE IP DEV LTD (GB) 2024-05-22 — — EP disclosed
CN-109563043-B Substituted pyridines as inhibitors of DNMT1 葛兰素史密斯克莱知识产权发展有限公司 2022-05-31 — — CN disclosed
US-10975056-B2 Substituted pyridines as inhibitors of DNMT1 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-04-13 — — US disclosed
US-10975056-B2 Substituted pyridines as inhibitors of DNMT1 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-04-13 — — US disclosed
US-20190194166-A1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-06-27 — — US disclosed
US-20190194166-A1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-06-27 — — US disclosed
EP-3468953-A1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 GlaxoSmithKline Intellectual Property Development Limited (GB) 2019-04-17 — — EP disclosed
WO-2017216727-A1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-12-21 — — WO disclosed
EP-1765805-A2 CGRP RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2007-03-28 — — EP disclosed
WO-2007016087-A2 HETEROCYCLIC BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2007-02-08 — — WO disclosed
WO-2006099268-A2 CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2006-09-21 — — WO disclosed
US-7060836-B2 Lactams as tachykinin antagonists PFIZER, INC (US) 2006-06-13 — — US disclosed
WO-2006044504-A1 CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2006-04-27 — — WO disclosed
WO-2005072308-A9 CGRP RECEPTOR ANTAGONISTS MERCK & CO INC (US) 2006-02-02 — — WO disclosed
WO-2005072308-A2 CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2005-08-11 — — WO disclosed
EP-1456200-A1 LACTAMS AS TACHYKININ ANTAGONISTS Pfizer Limited (GB) 2004-09-15 — — EP disclosed
US-20040132710-A1 Lactams as tachkinin antagonists PFIZER INC. 2004-07-08 — — US disclosed
WO-2003051868-A1 LACTAMS AS TACHYKININ ANTAGONISTS PFIZER LIMITED (GB) 2003-06-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040132710-A1 Lactams as tachkinin antagonists PROKR1, TACR2, TACR1 OPRM1 66/4885OPRD1 56/4885OPRK1 15/4885
US-10975056-B2 Substituted pyridines as inhibitors of DNMT1 DNMT1, DNMT3A, DNMT3B OPRM1 3444/4885OPRD1 2884/4885OPRK1 3911/4885
US-20190194166-A1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 DNMT1, DNMT3A, DNMT3B OPRM1 3444/4885OPRD1 2884/4885OPRK1 3911/4885
US-20240279338-A1 Combination Treatment of Cancer CD274, PDCD1, ENTPD1 OPRM1 2984/4885OPRD1 3380/4885OPRK1 3457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.